SCHEMBL15660902

SCHEMBL15660902

Cc1ccc(C(=O)c2c(-c3ccc(F)cc3)sc3cc(O)ccc23)cc1

nearest known ligand 0.85

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 19/20 0.85
ESR2 Q92731 10/20 0.62
MEN1 O00255 1/20 0.54
KMT2A Q03164 1/20 0.54
TDP1 Q9NUW8 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8631942 0.92 ESR1 (0.81) ESR1ESR2MEN1KMT2ATDP1
SCHEMBL7104864 0.92 ESR1 (1.00) ESR1ESR2MEN1KMT2ATDP1
SCHEMBL31683627 0.92 ESR1 (0.81) ESR1ESR2MEN1KMT2ATDP1
SCHEMBL31683574 0.88 ESR1 (0.74) ESR1ESR2MEN1KMT2ATDP1
SCHEMBL15659126 0.85 ESR1 (1.00) ESR1ESR2MEN1KMT2ATDP1
SCHEMBL1665657 0.85 ESR1 (0.86) ESR1ESR2MEN1KMT2ATDP1
SCHEMBL15659896 0.85 ESR1 (0.74) ESR1ESR2
SCHEMBL15661057 0.84 ESR1 (0.72) ESR1ESR2MEN1KMT2ATDP1
SCHEMBL8630381 0.84 ESR1 (0.80) ESR1ESR2MEN1KMT2ATDP1
SCHEMBL26158897 0.84 ESR1 (0.79) ESR1ESR2MEN1KMT2ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3192795-B1 COMPOSITIONS AND METHODS FOR TREATING ESTROGEN-RELATED MEDICAL DISORDERS UNIV ILLINOIS (US) 2020-12-02 EP claimed
EP-3192795-A1 COMPOSITIONS AND METHODS FOR TREATING ESTROGEN-RELATED MEDICAL DISORDERS The Board of Trustees of the University of Illionis (US) 2017-07-19 EP claimed
US-20170114052-A1 COMPOSITIONS AND METHODS FOR TREATING ESTROGEN-RELATED MEDICAL DISORDERS THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS 2017-04-27 US claimed
US-20150284357-A1 COMPOSITIONS AND METHODS FOR TREATING ESTROGEN-RELATED MEDICAL DISORDERS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-10-08 US claimed
EP-2912033-A1 COMPOSITIONS AND METHODS FOR TREATING ESTROGEN-RELATED MEDICAL DISORDERS The Board of Trustees of the University of Illinois (US) 2015-09-02 EP claimed
WO-2014066695-A1 COMPOSITIONS AND METHODS FOR TREATING ESTROGEN-RELATED MEDICAL DISORDERS THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2014-05-01 WO claimed
EP-3192795-B1 COMPOSITIONS AND METHODS FOR TREATING ESTROGEN-RELATED MEDICAL DISORDERS UNIV ILLINOIS (US) 2020-12-02 EP disclosed
US-10464930-B2 Compositions and methods for treating estrogen-related medical disorders THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2019-11-05 US disclosed
US-10160752-B2 Compositions and methods for treating estrogen-related medical disorders THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2018-12-25 US disclosed
EP-3192795-A1 COMPOSITIONS AND METHODS FOR TREATING ESTROGEN-RELATED MEDICAL DISORDERS The Board of Trustees of the University of Illionis (US) 2017-07-19 EP disclosed
US-20170114052-A1 COMPOSITIONS AND METHODS FOR TREATING ESTROGEN-RELATED MEDICAL DISORDERS THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS 2017-04-27 US disclosed
US-20150284357-A1 COMPOSITIONS AND METHODS FOR TREATING ESTROGEN-RELATED MEDICAL DISORDERS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-10-08 US disclosed
EP-2912033-A1 COMPOSITIONS AND METHODS FOR TREATING ESTROGEN-RELATED MEDICAL DISORDERS The Board of Trustees of the University of Illinois (US) 2015-09-02 EP disclosed
WO-2014066695-A1 COMPOSITIONS AND METHODS FOR TREATING ESTROGEN-RELATED MEDICAL DISORDERS THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2014-05-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10464930-B2 Compositions and methods for treating estrogen-related medical disorders HSD17B11, CYP19A1, ESR1 ESR1 3/4885ESR2 5/4885MEN1 781/4885
US-20150284357-A1 COMPOSITIONS AND METHODS FOR TREATING ESTROGEN-RELATED MEDICAL DISORDERS HSD17B11, CYP19A1, ESR1 ESR1 3/4885ESR2 5/4885MEN1 781/4885
US-10160752-B2 Compositions and methods for treating estrogen-related medical disorders HSD17B11, CYP19A1, ESR1 ESR1 3/4885ESR2 5/4885MEN1 781/4885
US-20170114052-A1 COMPOSITIONS AND METHODS FOR TREATING ESTROGEN-RELATED MEDICAL DISORDERS HSD17B11, CYP19A1, ESR1 ESR1 3/4885ESR2 5/4885MEN1 781/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.